{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:20:29Z","timestamp":1780392029200,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016048","name":"The University of Texas at Tyler","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R01HD099756-02"],"award-info":[{"award-number":["1R01HD099756-02"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R21AI148096-01"],"award-info":[{"award-number":["1R21AI148096-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI137080"],"award-info":[{"award-number":["R01 AI137080"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01 AI150508"],"award-info":[{"award-number":["U01 AI150508"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001465","name":"American Thoracic Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001465","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007130","name":"University of Texas System","doi-asserted-by":"publisher","award":["250439\/39411"],"award-info":[{"award-number":["250439\/39411"]}],"id":[{"id":"10.13039\/100007130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jgar.2021.12.010","type":"journal-article","created":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T02:06:37Z","timestamp":1639793197000},"page":"71-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8786-8851","authenticated-orcid":false,"given":"Shashikant","family":"Srivastava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jotam G.","family":"Pasipanodya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott K.","family":"Heysell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunavanthi D.","family":"Boorgula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawanda","family":"Gumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"McShane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie V.","family":"Philley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.12.010_bib0001","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1513\/AnnalsATS.201804-236OC","article-title":"Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. managed care health plan, 2008\u20132015","volume":"17","author":"Winthrop","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jgar.2021.12.010_bib0002","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.12.010_bib0003","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2021.12.010_bib0004","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2021.12.010_bib0005","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.drup.2012.04.001","article-title":"Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria","volume":"15","author":"van Ingen","year":"2012","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.jgar.2021.12.010_bib0006","doi-asserted-by":"crossref","first-page":"10340","DOI":"10.1021\/acs.jmedchem.8b01389","article-title":"Orally absorbed derivatives of the \u03b2-lactamase inhibitor avibactam. Design of novel prodrugs of sulfate containing drugs","volume":"61","author":"Gordon","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.jgar.2021.12.010_bib0007","first-page":"1081","article-title":"Inhibition of \u03b2-lactamases of mycobacteria by avibactam and clavulanate","volume":"72","author":"Soroka","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.12.010_bib0008","series-title":"Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes","year":"2018"},{"key":"10.1016\/j.jgar.2021.12.010_bib0009","doi-asserted-by":"crossref","first-page":"e01553","DOI":"10.1128\/AAC.01553-20","article-title":"Nouveau short-course therapy and morphism mapping for clinical pulmonary Mycobacterium kansasii","volume":"65","author":"Srivastava","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.12.010_bib0010","doi-asserted-by":"crossref","first-page":"e00810","DOI":"10.1128\/AAC.00810-20","article-title":"Comparison of a novel regimen of rifapentine, tedizolid, and minocycline with standard regimens for treatment of pulmonary Mycobacterium kansasii","volume":"64","author":"Chapagain","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.12.010_bib0011","doi-asserted-by":"crossref","first-page":"e00248","DOI":"10.1128\/AAC.00248-18","article-title":"Clofazimine for the treatment of Mycobacterium kansasii","volume":"62","author":"Srivastava","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.12.010_bib0012","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1128\/AAC.04441-14","article-title":"Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease","volume":"59","author":"Srivastava","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.12.010_bib0013","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.jgar.2021.12.010_bib0014","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/thoraxjnl-2017-210927","article-title":"British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"72","author":"Haworth","year":"2017","journal-title":"Thorax"},{"key":"10.1016\/j.jgar.2021.12.010_bib0015","doi-asserted-by":"crossref","first-page":"7557","DOI":"10.1128\/AAC.02995-14","article-title":"Intra- and extracellular activities of trimethoprim\u2013sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosis","volume":"58","author":"Davies Forsman","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.12.010_bib0016","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/nm.3262","article-title":"Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis","volume":"19","author":"Pethe","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jgar.2021.12.010_bib0017","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1128\/AAC.01204-07","article-title":"Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis","volume":"52","author":"Rustomjee","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.12.010_bib0018","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1128\/AAC.01354-09","article-title":"Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients","volume":"54","author":"Diacon","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.12.010_bib0019","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1128\/AAC.49.6.2289-2293.2005","article-title":"Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis","volume":"49","author":"Tyagi","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.12.010_bib0020","article-title":"Necrotizing pneumonia in a patient with untreated Mycobacterium kansasii infection","volume":"27","author":"Toor","year":"2019","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jgar.2021.12.010_bib0021","doi-asserted-by":"crossref","first-page":"698","DOI":"10.7326\/0003-4819-129-9-199811010-00004","article-title":"Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study","volume":"129","author":"Bloch","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jgar.2021.12.010_bib0022","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/clinids\/3.5.1025","article-title":"When is an infection disease?","volume":"3","author":"Wolinsky","year":"1981","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.jgar.2021.12.010_bib0023","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \u2018quality of evidence\u2019 and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jgar.2021.12.010_bib0024","first-page":"10","article-title":"Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii","volume":"135","author":"Ahn","year":"1987","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jgar.2021.12.010_bib0025","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40262-021-01000-6","article-title":"Therapeutic drug monitoring in non-tuberculosis mycobacteria infections","volume":"60","author":"Alffenaar","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jgar.2021.12.010_bib0026","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/pathogens9080641","article-title":"Preclinical models of nontuberculous mycobacteria infection for early drug discovery and vaccine research","volume":"9","author":"Rampacci","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.jgar.2021.12.010_bib0027","series-title":"Antibiotics in laboratory medicine","article-title":"Antimycobacterial agents: in vitro susceptibility testing, spectra of activity, mechanisms of action and resistance, and assays for activity in biologic fluids","author":"Inderlied","year":"1996"},{"key":"10.1016\/j.jgar.2021.12.010_bib0028","series-title":"Manual of clinical microbiology","first-page":"1149","article-title":"Susceptibility test methods: mycobacteria","author":"Inderlied","year":"2003"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521002848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521002848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:59:42Z","timestamp":1761991182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521002848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":28,"alternative-id":["S2213716521002848"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.12.010","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}